蒽环类药物所致心功能障碍的管理  

Management of cardiac dysfunction caused by anthracyclines

作　　者：张美岭[1] 邵群 张志仁 ZHANG Mei-ling;SHAO Qun;ZHANG Zhi-ren(Department of Cardiology,Onco-cardiology Center of Heilongjiang Province,Harbin Medical University Cancer Hospital,Harbin 150081,China)

机构地区：[1]哈尔滨医科大学附属肿瘤医院心血管内科黑龙江省肿瘤心脏病诊疗中心

出　　处：《肿瘤综合治疗电子杂志》2019年第3期13-17,共5页Journal of Multidisciplinary Cancer Management(Electronic Version)

基　　金：国家自然科学基金面上项目(81870370);哈尔滨医科大学附属肿瘤医院Nn10计划(Nn102017-04)

摘　　要：蒽环类药物被广泛用于治疗各种恶性实体肿瘤及血液、淋巴系统恶性肿瘤,也是常见的与心脏毒性作用相关的药物,且呈剂量依赖性,可引起不可逆的心肌损伤,最终导致心力衰竭。若能早期监测、预防,蒽环类药物引起的心脏毒性是可逆的。右丙亚胺是目前唯一可用于预防蒽环类药物相关心脏毒性的药物。Anthracyclines are widely used in the treatment of malignant solid tumors,hematological and lymphatic malignancies.They are also common drugs related to cardiotoxicity in a dose-dependent manner,which can cause irreversible myocardial damage and eventually lead to heart failure.Early monitoring and prevention,anthracycline-induced cardiotoxicity is reversible,and Dexrazoxane is currently the only drug used to prevent anthracycline-related cardiotoxicity.

关 键 词：蒽环类药物 心脏毒性 左室功能障碍 肌钙蛋白Ⅰ 右丙亚胺 

分 类 号：R979.1[医药卫生—药品]